News

Weis sees Q2 net income boost

BY Michael Johnsen

SUNBURY, Pa. — Weis Markets on Tuesday reported a 12.1% increase in its second-quarter net income to $23.2 million. For the period ended June 30, second-quarter earnings per share increased 11.7% to 86 cents per share, compared with 77 cents per share for the same period in 2011.

Second-quarter sales increased 0.1% to $677.1 million while comparable-store sales increased 0.4%.

Weis attributed its net income and operating income increases to disciplined promotions and marketing and a decrease in depreciation expenses when it changed depreciation methods from accelerated to straight-line.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?

View Results

Loading ... Loading ...
News

Yoplait goes ‘Simplait’

BY Allison Cerra

MINNEAPOLIS — Yoplait is going back to basics with its latest yogurt.

Yoplait Simplait yogurt is crafted from a combination of six ingredients, including cultured pasteurized grade A milk, fruit, sugar, corn starch, natural flavor and a vegetable or fruit juice or extract or pectin.

"Consumers are continually looking for new and different ways to enjoy the refreshing goodness of yogurt," Yoplait Simplait associate marketing manager Rachel Ringel said. "There has been an increasing demand for simpler ingredient lists, but one thing remains constant — taste is the most important."

Yoplait Simplait will be available nationwide this month in four flavors — strawberry, vanilla, peach and blackberry — and has a suggested retail price of 90 cents per single-serve cup.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?

View Results

Loading ... Loading ...
News

FDA approves Watson asthma generic

BY Alaric DeArment

PARSIPPANY, N.J. — The Food and Drug Administration has approved a generic drug designed to treat asthma in children.

Watson Pharmaceuticals announced Wednesday the approval of budesonide inhalation suspension in the 0.25-mg/2-mL and 0.5-mg/2-mL strengths. The drug is used to control and prevent asthma symptoms in children ages 12 months to 8 years.

The drug is a generic version of AstraZeneca’s Pulmicort Respules, which had sales of $1.1 billion during the 12-month period ended in May.


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?

View Results

Loading ... Loading ...